Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 14Esophageal Neoplasms 5Adenocarcinoma Of Esophagus 5Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Rectal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Multiple Myeloma 2Kidney Neoplasms 2Head and Neck Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Breast Carcinoma In Situ 2Vomiting 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Teratoma 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Prostate Adenocarcinoma 1Ovarian Neoplasms 1

Interventions

pembrolizumab 26atezolizumab 14Nivolumab 13Gemcitabine 13Cisplatin 10Docetaxel 8Carboplatin 8avelumab 7Mitomycin 7epacadostat 4cabozantinib 4Ipilimumab 4pemigatinib 3Specimen Handling 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Bevacizumab 3vofatamab 2rucaparib 2lenvatinib 2enfortumab vedotin 2durvalumab 2cabazitaxel 2bempegaldesleukin 2Standard of Care 2Rogaratinib 2Ramucirumab 2Radiation 2Platinum 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Transitional Cell × Neoadjuvant Therapy × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔